Physician

Liana Makarian, M.D.

According to 2025 Medicare claims, Liana Makarian, M.D. (NPI: 1730495250) practices hematology/oncology in the Columbia, MO market, with the plurality of this provider's patient population coming from Boone, MO. This provider's primary affiliated billing organization is MISSOURI CANCER ASSOCIATES LLC (NPI: 1215947338; TIN: 431763016) and primary practice location at 65201-7167. Makarian is affiliated with the Aledade 98 MO MSSP Enhanced (ACO ID: A4998), Aledade 93 National MSSP Enhanced (ACO ID: A5206), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Makarian's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,188 traditional Medicare patients, billed 323,203 HCPCS/CPT codes, and received $5,947,056 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,216 prescription claims across 485 beneficiaries totaling $4,780,855 in drug costs, led by Revlimid (Lenalidomide). DME data shows 81 claims. Open Payments data shows 245 records totaling $4,534. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $103,782 to $5,947,056. Similarly, Part D prescription costs have moved sharply higher in recent years, from $582,755 to $4,780,855. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $17,634 to $3,522.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	326	1,403	$103,782
2016	498	42,382	$515,577
2017	461	187,347	$1,939,481
2018	891	238,323	$3,475,708
2019	938	299,074	$3,844,020
2020	996	295,215	$4,183,393
2021	1,103	377,834	$5,075,443
2022	1,125	405,458	$4,790,732
2023	1,247	397,912	$5,161,742
2024	1,188	323,203	$5,947,056

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	218	1,665	$582,755
2016	274	1,826	$698,195
2017	220	1,719	$718,183
2018	272	2,209	$1,093,920
2019	362	2,549	$1,512,373
2020	350	2,863	$2,020,291
2021	386	3,224	$3,309,649
2022	435	3,119	$3,754,342
2023	481	3,172	$3,746,479
2024	485	3,216	$4,780,855

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	397	$16,855
2016	N/R	225	$7,235
2017	N/R	141	$19,637
2018	N/R	91	$12,902
2019	N/R	23	$2,923
2020	N/R	147	$95,052
2021	12	114	$7,851
2022	12	42	$3,666
2023	12	15	$1,808
2024	N/R	81	$1,982

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	497	1,393	$88
96413	Administration of chemotherapy into vein, 1 hour or less	234	634	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	273	326	$53
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	464	961	$12
96372	Injection of drug or substance under skin or into muscle	207	448	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	119	3,276	$2,000,830
Ibrance	Palbociclib	46	1,400	$765,597
Calquence	Acalabrutinib Maleate	16	660	$297,959
Jakafi	Ruxolitinib Phosphate	16	477	$271,614
Nubeqa	Darolutamide	15	450	$205,732

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	31	$1,198
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	25	$471
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	25	$314

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	245	$4,534	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Liana Makarian, M.D.?

Tedicare shows public-source Medicare data for Liana Makarian, M.D. (NPI 1730495250), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Liana Makarian, M.D. have ACO affiliation data?

Liana Makarian, M.D. is shown with ACO affiliation data for Aledade 98 MO MSSP Enhanced (MSSP, ACO ID A4998), Aledade 93 National MSSP Enhanced (MSSP, ACO ID A5206), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Liana Makarian, M.D.?

Liana Makarian, M.D. is linked to MISSOURI CANCER ASSOCIATES LLC (billing NPI 1215947338) in the available physician profile data.

Does Liana Makarian, M.D. have Open Payments data?

Liana Makarian, M.D. has 245 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.